Aptar acquires a leader in drug delivery training devices and patient onboarding

6 Nov 2019

Acquisition reflects movement of treatments being administered by patients at home rather than by healthcare providers.

AptarGroup has acquired Noble International, a leader in drug delivery training devices and patient onboarding. This acquisition furthers Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers through all stages of their drug development journey.

Aptar acquires a leader in drug delivery training devices and patient onboarding
Photo: courtesy of Noble International.

The proper administration of certain medications can be challenging, especially when patients are required to administer the medication themselves. With the movement of treatments from the healthcare provider to the home, the need to ensure accurate, consistent and safe use of the device becomes a critical component of the effectiveness of the treatment.

Noble’s purpose is to improve patient experiences and outcomes by developing patient-centric advanced drug delivery system training devices – including autoinjectors, prefilled syringes, on-body and respiratory devices – for the world’s leading biopharmaceutical companies and original equipment manufacturers. Noble has also developed a connected solution for injectable devices, which senses and monitors how a patient interacts with the specific steps of drug delivery and can wirelessly transmit real-time data.

Human behaviors and user experiences are critical elements of Noble’s proprietary training device design process. Combined with patient onboarding programs, Noble’s training devices - which mimic the feel, force and function of the actual drug delivery device - are designed to reduce error and increase device familiarity, both of which are keys to helping patients improve adherence and, ultimately, health outcomes.

Stephan Tanda, Aptar President and CEO, stated, “We are pleased to welcome the Noble team to the Aptar family. This strategic acquisition meets our disciplined approach of acquiring companies with strong positions in attractive markets, proprietary technologies and robust growth fundamentals. The combination of Noble and Aptar will bring additional value to our pharmaceutical customers as they seek to put more life-changing treatments into the hands of empowered patients. Together, we will work toward the ultimate goal of improving patient experiences and health outcomes.”

Noble, founded in 1994 and located in Orlando, Florida, employs 45 people at its state-of-the art training device design headquarters.

“Joining Aptar is an important step in our mission to support the healthcare community’s effort to improve patient outcomes through innovation, education and patient access,” said Jeff Baker, Noble CEO. “It is exciting to know that by leveraging the breadth of Aptar’s portfolio and global network, we will now reach more pharmaceutical partners, healthcare professionals, caregivers and, ultimately, patients.”

“We look forward to working with Noble’s leadership and team of innovators as we continue to improve the patient onboarding process,” comments Gael Touya, President of Aptar Pharma. “This acquisition, which expands our services offerings in Injectables and Respiratory, continues our strategy of building services associated with our device portfolio and speaks to our unwavering commitment to helping patients improve adherence.”

Read More

Related news

Novartis receives EC Approval for next-gen anti-VEGF treatment for wet AMD

Novartis receives EC Approval for next-gen anti-VEGF treatment for wet AMD

21 Feb 2020

Beovu is the only anti-VEGF treatment approved in Europe for wet AMD that offers the option to start eligible patients on 3-month dosing intervals immediately after the loading phase.

Read more 
The game is on for connected devices

The game is on for connected devices

20 Feb 2020

Global biologics markets, delivery device innovation and smart packaging ‘unpacking’ new growth opportunities for pharma.

Read more 
Management healthcare consultancy opens new offices in New York and London

Management healthcare consultancy opens new offices in New York and London

19 Feb 2020

The expansion will enable Putnam Associates to access the European market and to offer more localised support to its clients.

Read more 
CPhI South East Asia rescheduled for July 2020

CPhI South East Asia rescheduled for July 2020

18 Feb 2020

Event move ensures extra precautions and safety measures taken

Read more 
Sphere Fluidics expands to increase supply of surfactant for droplet microfluidics

Sphere Fluidics expands to increase supply of surfactant for droplet microfluidics

18 Feb 2020

Investment in resources to meet demand for large-scale supply of patented biocompatible surfactant.

Read more 
Dr Reddy's to acquire Wockhardt divisions

Dr Reddy's to acquire Wockhardt divisions

18 Feb 2020

Deal sees 62 brands in multiple therapy areas and a manufacturing plant transfer to the company

Read more 
Sartorius sharpens its brand focus

Sartorius sharpens its brand focus

17 Feb 2020

The company aims to simplify its customers’ work and thus help them to achieve medical progress and make innovative medicines available faster.

Read more 
FDA success for MedPharm Centre of Excellence

FDA success for MedPharm Centre of Excellence

14 Feb 2020

The inspection was triggered by data generated by MedPharm as part of a client’s ANDA for a generic topical product.

Read more 
Report predicts booming ASEAN generics export market for 2020

Report predicts booming ASEAN generics export market for 2020

13 Feb 2020

The changing opportunities are attributed to rising GMP standards and increased regional harmonization.

Read more 
Partnership formed to deliver effective biopharma industry testing

Partnership formed to deliver effective biopharma industry testing

12 Feb 2020

Stevanato and Pfeiffer Vacuum will provide biopharma companies with advanced container closure integrity analysis and testing protocols.

Read more